HC Wainwright & Co. Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $48
HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Price Target of $48.
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell
• R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 2)
BofA Initiates Praxis Precision Medical At Buy
Praxis Precision Medicines Inc’s (NASDAQ: PRAX) lead asset has demonstrated encouraging data for central nervous system diseases and has a broad pipeline that targets both prevalent and rare disorders, according to BofA Securities.
Clinicaltrials.gov Site Shows Praxis Precision Medicines Study ‘A Clinical Trial of 3 Doses of PRAX-944 in Participants With Essential Tremor’ Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05021991
B of A Securities Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $28
B of A Securities initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Price Target of $28.
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)